Can a Dual-Action antibody boost chemo against bile duct cancer?
Disease control
Not yet recruiting
This trial is testing whether adding ivonescimab to standard chemotherapy (gemcitabine and cisplatin) works better than the usual chemo-immunotherapy combination for people with advanced biliary tract cancer. Ivonescimab is a special antibody that targets two proteins: one that h…
Phase: PHASE2, PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC